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Edited by Francesc PosasAbstract Substantial actin remodelling occurs prior to mitosis
as cells alter their shape in preparation for cytokinesis. In mam-
malian cells, mitosis is initiated by a heterodimer of cyclin B1
and the cyclin dependent kinase 1 (Cdk1) serine/threonine ki-
nase. In this report. we show that human cyclin B1 binds the
actin cross-linking protein Filamin-A (FLNa). The proteins
co-immunoprecipitate and co-localize in mitotic human cells.
We ﬁnd that cyclin B1/Cdk1 can phosphorylate FLNa in vitro
and reduce its ability to gelate actin. We have also identiﬁed ser-
ine 1436 as one FLNa residue phosphorylated by cyclin B1/Cdk1
in vitro. Our results suggest a role for cyclin B1/Cdk1 in FLNa-
dependent actin remodelling.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cell cycle1. Introduction
Cell cycle progression is controlled by cyclin proteins and
their binding partners, the cyclin dependent kinases (cdks)
[1]. In mammalian cells, mitosis is initiated by the heterodimer
of cyclin B1 and cyclin dependent kinase 1 (Cdk1) [2–4]. Cyclin
B1/Cdk1 activation initiates mitosis through the phosphoryla-
tion of proteins controlling chromatin condensation and cyto-Abbreviations: AA, antibiotic/antimycotic; ABD, actin-binding do-
main; BSA, bovine serum albumen; b-arr, b-arrestin; CAM KII, cal-
cium/calmodulin-dependent protein kinase II; Cdk1, cyclin dependent
kinase 1; DAPI, 40,6-diamidino-2-phenylindole; D Box, destruction
box; ECM, extracellular matrix; ERK, MAPK extracellular signal-
regulated kinase; FBS, fetal bovine serum; FLNa, b, c, ﬁlamin A, B, C;
GFP, green ﬂuorescent protein; GST, glutathione S-transferase; HS-
P84/90b, heat shock protein 84/90b; IP, immunoprecipitation; MAPK,
mitogen activated protein kinase; PBS, phosphate buﬀered saline; P-
KCa, protein kinase Ca; SDS–PAGE, sodium dodecyl sulphate–pol-
yacrylamide gel electrophoresis; WB, Western blot; WCL, whole cell
lysate
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and Cdk1 kinase activity is required for G2/M transition [7]
and inhibition of cyclin B1 transcription is one mechanism
by which the p53 tumour suppressor inhibits mitosis [8].
As adherent mammalian cells prepare for mitosis, they as-
sume a rounded shape and the total contact area between
the cell and its growth substrate decreases [9]. Substantial
changes in the actin cytoskeleton occur during this process
[9]. In the ﬁssion yeast Schizosaccharomyces pombe, integrity
of the actin cytoskeleton is necessary for cells to undergo mito-
sis, and inhibition of actin polymerization by lantrunculin B
delays the completion of nuclear division [10]. Because of its
key role in mitotic initiation, cyclin B1/Cdk1 has long been
thought to be involved in mitotic actin remodelling in mamma-
lian cells [11]. Cyclin B1/Cdk1 can control actin remodelling
during mitosis, at least in part, by phosphorylating the actin
cross-linking protein caldesmon [12]. In this report, we show
that cyclin B1/Cdk1 interacts with and can partially regulate
the function of the actin cross-linking protein Filamin-A
(FLNa, ABP280, FLN1).
Filamins are large (280 kDa) cytoplasmic proteins initially
identiﬁed by their ability to bind ﬁlamentous actin from non-
muscle cells [13]. There are three mammalian Filamins (FLNa,
FLNb and FLNc). Each protein contains an amino-terminal
actin-binding domain (ABD), a long rod-like domain of 24 re-
peats and two ﬂexible hinge-like structures (Fig. 1A). Repeats
are believed to be docking sites for ﬁlamin-binding proteins
[15]. Filamins homodimerize via repeat 24 and form a V-
shaped structure [13]. The hinges, one between repeats 15
and 16 and the other between 23 and 24, are predicted to allow
for conformational ﬂexibility of the FLNa molecule. Of the
three human ﬁlamin isoforms, FLNa is the most abundant
and widely expressed [14]. FLNb also has a broad tissue distri-
bution, but is less abundant than FLNa. FLNc is predomi-
nantly expressed in cardiac and skeletal muscle [14]. Filamins
are involved in cross-linking cortical actin and can organize ﬁl-
amentous actin into stress ﬁbres and three-dimensional gel-like
networks [14]. Filamins also act as scaﬀolding proteins that
link cytoplasmic signalling proteins to the actin cytoskeleton.
FLNa is known to bind the GTPase RalA [15] and Trio, a
guanine nucleotide exchange factor that is able to induce ac-
tin-based ruﬄing in cells [16]. In addition, granzyme B and
the androgen receptor interact with FLNa between hinge 1
and 2 in the FLNa carboxyl-terminus [14,15,17,18].
In this report, we show that cyclin B1 binds to human FLNa
and the two proteins co-immunoprecipitate in human cells.
Cyclin B1 and FLNa also co-localize in mitotic cells. We ﬁnd
that cyclin B1/Cdk1 phosphorylate FLNa and decrease itsation of European Biochemical Societies.
Fig. 1. Interaction between cyclin B1 and Filamin A. (A) Schematic diagram of a FLNa dimer. The protein contains an amino-terminal actin-
binding domain (ABD), 24 repeats, 2 hinges and a carboxyl-terminal dimerization domain. Adapted from Stossel et al. [14]. (B) Domain structure of
cyclin B1 indicating the D-box, the CRS (cytoplasmic retention sequence) and the Cyclin box. Phosphorylation sites within the CRS are also
indicated. The fragment of cyclin B1 used in our two-hybrid screen includes the D-box. (C) Comparison of the interactor sequence from the screen
indicates near complete identity with human FLNa. Mouse and human FLNa have high sequence identity. This region of human FLNa spans part of
repeats 8 and 10 and all of repeat 9. (D) Actin structure in human HeLa cells diﬀers between interphase and mitotic cells. The yellow scale bar is
10 lM.
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cyclin B1/Cdk1 can elicit changes in the actin cytoskeleton
by phosphorylating FLNa and reducing its ability to cross-link
actin.2. Materials and methods
2.1. Yeast two-hybrid
The yeast two hybrid was performed as previously described [19]. The
pLexA pBTM116 cyclin B1 bait plasmid (pLex-B1) was constructed
using the amino-terminal 53 amino acids of cyclin B1 using the primers
5 0GACCCGGGGGCGCTCCGAGTCACCAGG3 0 (sense) and 50CA-
GTCGACGTTAACTGACTTTGTTACCAAT30(anti-sense). The PCR
fragment was digested with SmaI and SalI and inserted into the SmaI/
SalI site of pBTM116. A mouse 10.5 day old embryonic library cloned
into the VP16 plasmid was used as prey. Histidine-positive colonies of
L40 yeast were lysed in liquid nitrogen and assayed for b-galactosidase
activity on ﬁlters. Positive colonies were further analyzed after loss of
the pLex-B1 plasmid and if no self-activation occurred, inserts from
b-galactosidase positive colonies were sequenced. Sequences were ana-
lyzed using the National Center for Biotechnology Information (NCBI)
nucleotide BLAST database.
2.2. Cell culture
HeLa cells and 293 cells were purchased from the American Type
Culture Collection (ATCC; Manassas, VA). M2 and A7 were gifts
from Dr. Thomas Stossel (Brigham and Women’s Hospital, Harvard
Medical School). HeLa cells were maintained in Minimal Essential
Medium alpha (Invitrogen Life Technologies, Burlington, Ont., Can-
ada) supplemented with 10% fetal bovine serum (FBS) and 1% antibi-
otic/antimycotic (AA) (Invitrogen). 293 cells were maintained in
Dulbecco Modiﬁed Eagle medium (Invitrogen) supplemented with
10% FBS and 1% AA. M2 and A7 cells were maintained in Minimal
Essential Media supplemented with 10% FBS, 1% AA, 1% sodium
pyruvate, 1% L-glutamine, 10 mM HEPES (Invitrogen) and the A7
cells were also supplemented with 0.5 mg/ml of G418 (Invitrogen).
All cell lines were maintained at 37 C in a humidiﬁed atmosphere with
5% CO2.
2.3. Plasmid DNA and transfections
GFP-tagged cyclin B1 was a gift of Dr. Anja Hagting (Wellcome/
CRC Institute) and FLNa was a gift of Dr. Fumihiko Nakamura
(Brigham and Women’s Hospital, Harvard Medical School). For
transfection, M2, A7 and HeLa cells were seeded at 3.0 · 105 cells in
100 mm plates and transfected the following day with ExGen 500 (Fer-
mentas Life Sciences, Burlington, Ont., Canada) according to manu-
facturers protocol.
2.4. Co-immunoprecipitation and immunoblotting
HeLa and 293 cells were treated with 100 ng/ml nocodazole (Sigma–
Aldrich, Oakville, Ont., Canada) overnight (14–16 h). The next day,
cells were collected, lysed in a buﬀer of 1% NP-40, 50 mM Tris pH
7.4, 5 mM EDTA, 150 mM NaCl containing a 1· protease inhibitor
cocktail (Sigma), left on ice for a minimum of 30 min and centrifuged
at 4 C for 10 min. at 14000 rpm. The supernatant was collected and
protein concentration was determined using the Bradford method
(BioRad, Mississauga, Ont., Canada). Antibodies used were ﬁlamin-
A (Neomarkers, Montreal, Que., Canada; Chemicon International,
Temecula, CA and Santa Cruz, Santa Cruz, CA), cyclin B1 (Neomar-
kers and Santa Cruz), myt1 (Santa Cruz), normal mouse (Santa Cruz),
actin (MP Biomedicals, Aurora, OH) and MPM2 (Upstate Biotechnol-
ogy, Lake Placid, NY). For co-precipitation, 250–750 lg of cell lysate
was incubated with 0.5–1 lg of cyclin B1, FLNa, normal mouse, GFP
(Santa Cruz) or FLAG (Sigma) antibody. The mixture was incubated
from one hour to overnight at 4 C with gentle rocking. Lysates were
then incubated with protein-A or G beads (Sigma and Santa Cruz)
from 1 h to overnight at 4 C. Beads were washed 3· with lysis buﬀer
and the beads were eluted with 2· SDS sample buﬀer by boiling for
8 min. Samples were resolved by 7.5–12% gradient SDS–PAGE and
transferred to nitrocellulose (Schleicher & Schuell, Keene, NH). Blots
were then blocked with 5% milk in TBS-T (20 mM Tris pH 7.5,
150 mM NaCl and 0.1% Tween 20) for between 1 hr to overnight at4 C, washed in TBS-T 3· totalling 15 min. (this wash step was done
between each treatment), probed with the speciﬁc primary antibody
indicated in each ﬁgure overnight at 4 C, washed, incubated with a
horseradish peroxidase secondary antibody (BioRad) for 45 min.,
washed, treated with ECL (Amersham Biosciences, Piscataway, NJ)
and exposed to X-ray ﬁlm.
2.5. Glutathione S-transferase (GST) protein construction
Human FLNa fragments were cloned into pGEX-4T1 vector (Phar-
macia). The FLNa fragments are FLNa-1, 33 kDa representing the ac-
tin-binding domain; FLNa-2, 110 kDa, repeats 1–10; FLNa-3, 60 kDa,
repeats 11–16 and FLNa-4, 80 kDa, repeats 17–24. GST-FLNa fusion
proteins were expressed in Escherichia coli BL-21 cells (Invitrogen)
according to standard protocols, and aﬃnity puriﬁed by glutathione-
sepharose-4B beads (Amersham Biosciences) and Thrombin (Amer-
sham Biosciences) cleaved to remove the GST moiety. Three mutants
were created in repeats 12–15 using PCR mutagenesis and cloned into
pGEX-4T1. The mutated sites are serine 1436 (SPFKﬁ GPFK), ser-
ine 1533 (RSPFKﬁ RGPFK) and serine 1630 (SPYRﬁ APYR). Cy-
clin B1 fragments corresponding to amino-terminal amino acids 1–40
of cyclin B1; amino-terminal amino acids 40–53 of cyclin B1; amino-
terminal amino acids 1–53 of cyclin B1; a deletion mutant lacking
the ﬁrst 53 amino acids; and a full length cyclin B1 construct were
cloned into the pGEX-4T1 vector. All constructs were sequenced be-
fore use.
2.6. In vitro cyclin B1/FLNa interaction
For experiments with whole cell lysates (WCL) and baculovirus
puriﬁed FLNa, GST linked cyclin B1 proteins were loaded onto
30 ll of glutathione sepharose-4B beads, left at room temperature
rotating for 30 min to 2 h and washed 3· with phosphate buﬀered sal-
ine (PBS). The beads containing the GST-cyclin constructs were then
incubated with 1 mg of total 293 or HeLa lysates in RIPA buﬀer
(150 mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% deoxycholate
and 0.1% SDS) or 357 ng of FLNa for 30 min to overnight at 4 C.
Samples were then washed 3· in PBS. The binding of recombinant
FLNa constructs to recombinant GST-cyclin B1 constructs was car-
ried out by combining equal amounts of the GST cyclin B1 and FLNa
(GST free) with 30 ll of glutathione sepharose-4B beads as above. Pre-
cipitated proteins were detected by a mixture of antibodies that detect
distinct FLNa regions: Neomarkers FLN Ab-1, Santa Cruz FLNa E-3
and FLNa H-300 as well as Chemicon FLNa mab1680 according to
manufacturer’s instructions.
2.7. In vitro cyclin B1/Cdk1 phosphorylation
Human FLNa was puriﬁed from HeLa cells according to a previ-
ously published protocol [20]. Human FLNa expressed in baculovirus
was puriﬁed according to Nakamura et al. [21]. Cyclin B1/Cdk1 was
either purchased as an active enzyme derived from recombinant pro-
teins (Upstate) or immunopuriﬁed from HeLa cells. For immunopu-
riﬁcation, HeLa were treated with 100 ng/ml nocodazole (Sigma)
overnight and active kinase immunoprecipitated with a cyclin B1 anti-
body and protein-G beads as above. Beads were washed 2· in lysis
buﬀer (same as above) they were then washed 2· in E1A buﬀer
(50 mM Tris pH 7.4, 1 mM EDTA, 0.5% NP-40, 250 mM NaCl), then
washed 3· in kinase buﬀer (50 mM HEPES pH 7.0, 5 mM MnCl2,
10 mM MgCl2, 0.8 mM EGTA). The beads were left in kinase buﬀer
and 10 lCi of 32P-ATP and 0.05 mM cold ATP was added for 30 min.
The reaction was stopped by the addition of 2· SDS sample buﬀer,
samples were boiled for 8 min, loaded onto 10% PAGE, dried and ex-
posed to a phosphorimager screen and/or Storm 860 phosphorimager
(Molecular Dynamics, Sunnyvale, CA) or autoradiography. Quantita-
tion was performed using ImageQuant TL software (Molecular
Dynamics). In the case of recombinant cyclin B1/Cdk1, the kinase as-
say was performed according to manufacturers instructions using
10 lCi [c  32P]-ATP and 1 mM ATP. Kinase reactions were electo-
phoresed and quantitated as above or blotted onto P30 ﬁlter paper
as per the manufacturer’s instructions, added to BetaMax scintillation
ﬂuid (ICN Biomedicals, Irvine, CA, USA) and counted with a Wallac
1414 Liquid Scintillation Counter (Fisher Scientiﬁc Limited, Ottawa,
Ont., Canada). Chicken gizzard FLN (RDI, NJ) and thrombin
cleaved GST puriﬁed human FLNa constructs were also used as sub-
strates for immunopuriﬁed cyclin B1/Cdk1 using the kinase protocols
above.
Table 1
Cyclin B1 interactors
Gene Hits GI accession
Filamin A (FLNa) 1 13752160
Mouse HSP84 (HSP90b) 6 194026
Mouse BMS1-like ribosome
assembly protein
1 21410150
Mouse Pax3 transcription
factor
1 6679210
Mouse ribosomal protein
L4 (Rpl4)
1 31340596
Mouse mitochondrial carrier
triplet repeat 1 (Mcart1)
1 57977298
Mouse up-stream binding
factor (UBF) transcription factor
1 20913288
Mouse nicalin homolog (zebraﬁsh)
(Ncln)
1 33469042
Mouse U1 small nuclear
ribonuclearprotein 70 kDa
2 12852074
Mouse Peroxiredoxin I 1 54035545
Mouse PCNA 1 26353219
Mouse signal peptide, CUB domain,
EGF-like 1 (Scube1)
1 12738839
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The ability of FLNa to gelate actin was measured by an actin sedi-
mentation assay (Cytoskeleton, Denver, CO) or by falling ball viscom-
etry [21]. For falling ball viscometry, FLNa was incubated with either
cyclin B1/Cdk1 or bovine serum albumen (BSA) at 30 C for the times
incubated in the ﬁgure legends and then added to an actin polymeriza-
tion solution containing 23 lM G-actin according to manufacturer’s
instructions (Cytoskeleton) in a ﬁnal volume of 100 ll. Samples were
then loaded into a capillary tube and incubated for 1-h at room tem-
perature and viscosity measured as described [21], except that Blue
Tack (Home Depot, Ont., Canada) was used to seal the capillary.
For actin sedimentation, FLNa was added to protein-G beads contain-
ing immunopuriﬁed cyclin B1/Cdk1 and the kinase reaction was car-
ried out as above, followed by removal of the supernatant
containing FLNa. Puriﬁed polymerized actin (Cytoskeleton) was
added to the samples at room temperature for 1 h, followed by
14000 rpm spinning at 4 C for 30 min. The supernatant was then re-
moved and the pellet resuspended in 2· SDS sample buﬀer, heated at
80 C for 8 min and electrophoresed on a 10% PAGE gel. The gel was
then stained in Coomassie brilliant blue solution overnight at room
temperature, de-stained and dried. Gelled actin was quantitated using
an Alpha Innotech video documentation device and quantitated using
Alpha Imager software. Roscovitine (1.3 lM ﬁnal concentration) and
olomoucine (14 lM ﬁnal concentration) (Calbiochem, San Diego, CA)
were added to the immunopuriﬁed cyclin B1/Cdk1 complexes in kinase
buﬀer (50 mMHEPES pH 7.5, 1 mMDithithreitol, 0.02% (w/v) Tween
20, 100 mM NaCl) and incubated at RT for 30 min, after which the
beads were washed in kinase buﬀer (50 mM HEPES pH 7.0, 5 mM
MnCl2, 10 mM MgCl2, 0.8 mM EGTA) and incubated as above in
the presence of the inhibitors.
2.9. Immunoﬂuorescence
Cells were treated as stated previously [22]. Brieﬂy, cells were plated
on coverslips, washed twice with PBS and ﬁxed with 4% paraformalde-
hyde at 4 C for 1 h, and washed 3· with PBS over 20 min (same for
all wash steps). Cells were then washed and permeabolized (0.02% tri-
ton-X 100 in PBS) for 5 min, followed by washing and blocking in 5%
normal goat serum for between 1 h and overnight. The blocker was re-
moved and cyclin B1 Ab-3 or Ab-4 (Neomarkers) 1:500 was added to
the cells for between 1 h to overnight at 4 C. Following PBS wash,
1:500 Alexa-conjugated 546 nm goat anti-mouse secondary (Molecular
Probes, Eugene, OR) was added for 30 min, washed, and 1:1000 FLNa
Ab-1 (Neomarkers) was added for 1 h to overnight at 4 C. Following
PBS wash, 1:500 Alexa-conjugated 488 nm goat anti-mouse secondary
was added for 30 min, washed, and 4 0,6-diamidino-2-phenylindole
(DAPI) (Sigma) was added for 10 min followed by a wash. Cells were
stained with DAPI (Sigma) to visualize DNA and actin was visualized
using AlexaFluor 546 phalloidin (Molecular Probes). Slides were im-
aged using a Leica DMIRB inverted stage microscope and deconvo-
luted using Open Lab software (Improvision, Lexington, MA).3. Results
3.1. Two hybrid analysis identiﬁes FLNa as a cyclin B1
interacting protein
To identify proteins that interact with cyclin B1, we used a
yeast two-hybrid screen utilizing the amino-terminal 53 amino
acids of human cyclin B1 as bait (Fig. 1B). This portion of cy-
clin B1 includes the destruction box (D-box), a region of the
protein that regulates proteolytic destruction of cyclin B1
[23]. We used a mouse embryonic 10.5 day old cDNA library
as prey and screened 1 · 107 colonies. A list of interactors
with identiﬁable homology is shown in Table 1. The most com-
monly identiﬁed interactor was mouse HSP84/HSP90b, likely
due to its capacity to bind unfolded proteins. Other interactors
include the Pax3 transcription factor, ribosomal proteins,
PCNA and peroxiredoxin I. Both PCNA and peroxiredoxin
I have previously been shown to interact with cyclin B1/
Cdk1 [24,25], suggesting that our screen is identifying bonaﬁde cyclin B1 interacting proteins. We decided to pursue FLNa
as a cyclin B1 interactor because of the marked diﬀerences in
actin structure between interphase and mitotic cells
(Fig. 1D). Mitotic cells have fewer and shorter stress ﬁbres
and ectopic expression of cyclin B1/Cdk1 has previously been
reported to alter the actin cytoskeleton [11]. We reasoned that
regulation of FLNa activity could be one possible pathway
through which cyclin B1/Cdk1 might aﬀect actin remodelling
at mitosis. The FLNa domain that interacts with cyclin B1 in-
cludes all of FLNa repeat 9 and part of repeats 8 and 10
(Fig. 1A).
3.2. Interaction of cyclin B1 and FLNa in mammalian cells
In order to conﬁrm a physical interaction between human
FLNa and cyclin B1, we next determined whether cyclin B1
and FLNa could co-precipitate in human cells. The abundance
of cyclin B1 is very low in normally cycling cells because of the
small number of cells entering into mitosis. We therefore in-
creased cyclin B1 protein levels in human HeLa and 293 cells
by treating them with nocodazole, a microtubule destabilizing
agent that arrests cells in G2/M, increasing cyclin B1 protein
levels and cyclin B1/Cdk1 kinase activity [26]. Nocodazole in-
creases cyclin B1 protein levels but has no eﬀect on FLNa
(Fig. 2A). As shown in Fig. 2B, a cyclin B1 antibody immuno-
precipitates a detectable amount of FLNa in HeLa and 293
cells treated with nocodazole (top panels). FLNa was not pre-
cipitated by control normal mouse serum. There is no detect-
able actin in the immunoprecipitates (lower panels),
indicating that the FLNa/cyclin B1 co-precipitation is not
due to indirect association of either protein with actin. While
co-precipitation is detectable, only a small fraction of FLNa
is associated with cyclin B1, likely due to the large intracellular
excess of FLNa relative to cyclin B1. To determine whether
FLNa and cyclin B1 interact in untreated cells and to deter-
mine if there is a reciprocal interaction between the two pro-
teins, we next transfected M2 cells, a human melanoma cell
line lacking endogenous FLNa, with cyclin B1 and FLNa.
We used a GFP-cyclin B1 allele for transfection so that the
molecular weight of the transfected protein (90 kDa) was dis-
tinguishable from the heavy chain of the precipitating anti-
Fig. 2. Cyclin B1 binds to human FLNa. (A) Nocodazole (100 ng/ml) treatment of HeLa cells increases cyclin B1 protein levels but not FLNa. (B)
Co-immunoprecipitation of cyclin B1 and FLNa in human 293 and HeLa cells treated with nocodazole (100 ng/ml). The upper panel is a Western
blot for FLNa from whole cell lysate (WCL), or FLNa, cyclin B1 or normal mouse IgG immunoprecipitation. FLNa is approximately 280 kDa. The
lower panel is the same immunoprecipitation blotted for actin. (C) Cyclin B1 co-immunoprecipitates with FLNa in FLNa-deﬁcient M2 cells
transfected with FLNa and a GFP-cyclin B1 allele (left panel). Antibodies used for immunoprecipitation are indicated. Normal mouse serum and
FLAG serve as controls. GFP-cyclin B1 was detected by blotting with a cyclin B1 antibody. (Right panel) Cyclin B1 co-immunoprecipitates with
FLNa in ﬁlamin-containing HeLa and A7 cells transfected with a GFP-cyclin B1 allele.
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tates cyclin B1 in M2 cells (left panel). Cyclin B1 is also precip-
itated by a GFP antibody but not by control normal mouse
serum or a FLAG antibody control. Transfection of GFP-
tagged cyclin B1 into the FLNa-expressing human cell lines
HeLa and A7 similarly shows cyclin B1 co-immunoprecipita-
tion with FLNa (Fig. 2C, right panel). A7 is an M2 variant
that has been engineered to express FLNa at normal levels.
We have performed co-immunoprecipitation experiments with
multiple cyclin B1 and FLNa antibodies from diﬀerent com-
mercial sources with similar results (not shown), indicating
that FLNa and cyclin B1 physically interact.
3.3. Interaction of puriﬁed cyclin B1 with FLNa
To further examine the cyclin B1-FLNa interaction, we cre-
ated recombinant GST proteins containing our initial bait and
smaller fragments thereof. These fragments correspond to the
initial bait (amino acids 1–53), the D-box (amino acids 42–50)
and non-D-box fragment (amino acids 1–40). These GST-pro-
teins were incubated with whole cell lysates from HeLa and
293 cells to determine whether they could precipitate FLNa.
As shown in Fig. 3A, amino acids 1–40 and 1–53 both bind
FLNa in the cell lysates, whereas the construct with amino
acids 40–53 and the GST protein did not. We then determined
whether baculovirus puriﬁed human FLNa could interact with
these proteins. As shown in Fig. 3B (top panel), cyclin B1 ami-
no acids 1–40, full length cyclin B1, and to a lesser extent ami-
no acids 1–53 bound to FLNa. A small background FLNa
band is detectable in 40–53, 54–433 and GST alone lanes. This
background binding may be due to a small amount of FLNa
binding the glutathione sepharose beads since the BL-21 lysatealone also shows some binding (Fig. 3B). A Coomassie stain of
the baculovirus FLNa is shown in the lower panel of Fig. 3B.
Taken together, these results map the FLNa interaction do-
main to cyclin B1 amino acids 1–40.
We determined whether amino acids 1–40 could interact
with regions of FLNa other than those identiﬁed from the
two hybrid screen. To this end, we created truncated versions
of FLNa: FLNa-1 (FLNa actin-binding domain; MW:
33 kDa), FLNa-2 (FLNa repeats 1–10; MW: 110 kDa),
FLNa-3 (FLNa repeats 11–16; MW: 60 kDa) and FLNa-4 (re-
peats 17–23 and dimerization domain; MW: 80 kDa). These
proteins are schematically depicted in Fig. 3C. FLNa-2 binds
detectably to cyclin B1 1–40 and no interaction was observed
with either FLNa-3 or FLNa-4. (Fig. 3D, left panel) There is
some interaction between FLNa-1 to cyclin B1 depicted in
Fig. 3D (left panel), but this interaction is not consistently ob-
served. FLNa-2 interacts with cyclin B1 residues 1–40 and does
not appreciably bind cyclin B1 residues 54–433 or GST
(Fig. 3E). Taken together, our data suggest a model for cyclin
B1/FLNa interaction where cyclin B1 amino acids 1-40 bind
the FLNa amino-terminal region in repeat 9.
3.4. Cyclin B1 and FLNa co-localize in human cells
To establish that cyclin B1 and FLNa interact in intact cells,
we used deconvolution immunoﬂuorescence to determine the
intracellular localization of both proteins as a function of the
cell cycle. Cyclin B1 and FLNa proteins co-localize strongly
in mitotic cells in telophase and metaphase (Fig. 4). In inter-
phase cells, cyclin B1 and FLNa have little super-imposable
distribution suggesting that the two proteins interact primarily
in mitotic cells. To conﬁrm the speciﬁcity of mitotic cyclin B1/
Fig. 3. Mapping cyclin B1/FLNa interaction sites. (A) GST fusion proteins derived from the indicated cyclin B1 amino acids were incubated with
either HeLa or 293 total cell lysates. Bound FLNa is detected by Western blotting for FLNa. (B) Cyclin B1 GST constructs bind puriﬁed FLNa. GST
fusion proteins derived from the indicated cyclin B1 amino acids were incubated with baculovirus puriﬁed human FLNa and bound FLNa detected
by Western blotting. BL-21 bacterial lysates were used as a control. Coomassie stained baculovirus puriﬁed human FLNa is shown in the lower
panel. (C) Schematic depiction of FLNa truncations used for cyclin B1 interaction analysis. (D) FLNa-2 is the major site for cyclin B1 interaction.
One microgram of cyclin B1 amino acids 1–40 was incubated with 1 lg of the indicated FLNa fragments (FLNa 1–4) and bound FLNa detected by
Western blotting for FLNa (left panel). Four diﬀerent FLNa antibodies were used to blot the membrane. The input FLNa fragments are shown in a
Coomassie gel in the right panel. (E) GST-cyclin B1 amino acids 1–40 and 54–433 were incubated with the FLNa-2 fragment and interacting proteins
detected by Western blotting for FLNa. GST alone, beads alone and BL-21 cells alone were controls.
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protein also co-localizes with FLNa. Myt1 is involved in the
inhibitory phosphorylation of Cdk1 at threonine 14 during
prophase of the cell cycle, and is localized to the endoplasmic
reticulum and Golgi complex both during interphase and mito-
sis [27]. As is shown in Fig. 4C, the Myt1 protein is cytoplas-
mic at interphase. In mitotic cells, the distribution of Myt1 and
FLNa does not show substantial super-imposable distribution.
This indicates that the co-localization of cyclin B1 with FLNa
in mitotic cells is speciﬁc.
3.5. Cyclin B1/Cdk1 phosphorylate FLNa
Cyclin B1/Cdk1 is known to phosphorylate the actin associ-
ated proteins actopaxin, paxillin and caldesmon [28–30]. FLNais a substrate for the kinases p21-activated kinase-1 (Pak1) [31]
and protein kinase Ca[32]. We next determined whether FLNa
(puriﬁed from chicken gizzard, human cells, or baculovirus)
could be substrates for cyclin B1/Cdk1 kinase activity. As
shown in Fig. 5A, puriﬁed recombinant cyclin B1/Cdk1 (Up-
state) phosphorylates human FLNa in a time- and dose-depen-
dent manner (upper and lower panels, respectively).
Phosphorylation of FLNa is maximal at 1 h. Recombinant
cyclin B1/Cdk1 (Upstate) phosphorylates baculovirus puriﬁed
human FLNa and immunopuriﬁed cyclin B1/Cdk1 phosphor-
ylates chicken gizzard FLN in a dose-dependent fashion
(Fig. 5B, bottom and top, respectively).
To further explore FLNa phosphorylation by cyclin B1/
Cdk1, we determined whether full length FLNa contained an
Fig. 4. Cyclin B1 and FLNa co-localize in mitotic and interphase cells. (Left panels) HeLa cells at the labelled cell cycle phases were stained for cyclin
B1 (red), FLNa (green) and DNA (blue). Co-localization of cyclin B1 and FLNa is indicated by the yellow colour in the merged picture. (Right
panels) As a control, HeLa cells were also stained with Myt1 (green), FLNa (red) and DNA (blue). The lack of yellow colour in the merged picture
indicates that Myt1 does no co-localize with FLNa in either interphase or mitotic cells. The yellow scale bar is 10 lM.
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many proteins during mitosis and is generated by Cdk1, ERK2
and Plk [33,34]. As shown in Fig. 5C, FLNa immunoprecipi-
tated from untreated HeLa cells contains an mpm-2 epitope
(upper panel) and mpm-2 reactivity increases following noco-
dazole treatment (bottom panel). Nocodazole treatment in-
creases cyclin B1 levels (Fig. 2A) and activates intracellular
cyclin B1/Cdk1 activity. Nocodazole treatment has no aﬀect
on FLNa levels in these cells (Fig. 2A). Taken together, these
results indicate that FLNa is an in vivo as well as an in vitro
substrate for cyclin B1/Cdk1 activity.
3.6. Cyclin B1/Cdk1 inhibits FLNa-dependent actin gelation
To determine whether cyclin B1/Cdk1 phosphorylation
could regulate FLNa function, we next determined whether cy-
clin B1/Cdk1 could directly regulate FLNa gelation in vitro.
Gelation by FLNa involves the solidiﬁcation of polymerized
actin into a cross-linked network [21]. It has been shown pre-
viously that Ca2+/calmodulin-dependent protein kinase II
(Cam KII) phosphorylation of chicken gizzard FLN caused
a decrease in the gelation capacity of FLN [35], and we wanted
to determine whether cyclin B1/Cdk1 could similarly aﬀect
FLNa’s ability to gel actin. As shown in Fig. 6A, FLNa that
has been incubated in vitro with cyclin B1/Cdk1 showed a
reproducible decrease in its ability to gel actin (Fig. 6A, left pa-
nel, lane 4) compared to untreated FLNa (Fig. 6A, lane 3). To
conﬁrm the speciﬁcity of this inhibition, we tested the ability of
the Cdk1 kinase inhibitors roscovitine and olomoucine to res-
cue gelation from Cdk1 inhibition [36]. As shown in Fig. 6B,
both roscovitine and olomoucine (Fig. 6B, lanes 5 and 6)
reproducibly prevented cyclin B1/Cdk1 from attenuating theability of FLNa to gel actin. a-Actinin is a protein used as a
positive control for actin gelation (Fig. 6B, lane 7). To conﬁrm
these observations, we determined whether phosphorylation of
FLNa by cyclin B1/Cdk1 altered the ability to FLNa to in-
crease the apparent viscosity of an actin polymer solution.
Solution viscosity is a measure of gelation. As shown in
Fig. 6C (left panel), FLNa increases the viscosity of an actin
solution in a dose-dependent manner. However, incubation
of FLNa with increasing amounts of cyclin B1/Cdk1 inhibits
this viscosity increase (right panel). Incubation of FLNa with
BSA had no eﬀect.
3.7. Serine 1436 is an in vitro phosphorylation site on FLNa
In order to identify domains of FLNa that were phosphory-
lated by cyclin B1/Cdk1, we tested the GST-FLNa constructs
from Fig. 3 (GST-FLNa 1–4) as substrates for cyclin B1/
Cdk1 kinase activity. As shown in Fig. 7A, the FLNa-3 frag-
ment, corresponding to repeats 11–16, showed the highest level
of phosphorylation by cyclin B1/Cdk1. We observed phos-
phorylation in the other FLNa fragments, but at a lower level
than was observed in FLNa-3. We then generated smaller
FLNa constructs based on the previous results and narrowed
the major phospho-acceptor sites in FLNA-3 to repeats 12–
15 of FLNa (not shown). Phosphorylation of these repeats
by cyclin B1/Cdk1 generates an mpm-2 epitope in vitro
(Fig. 7B), consistent with the idea that this sequence contains
one or more sites for cyclin B1/Cdk1 activity. There is endog-
enous mpm2 phosphorylation present in our puriﬁed protein
and cyclin B1/Cdk1 autophosphorylates itself generating an
mpm2 epitope. Cdk1 has a phosphorylation consensus se-
quence of (K/R)(S/T)P X(K/R) or (S/T)P X(K/R) [37] (where
Fig. 5. Cyclin B1/Cdk1 phosphorylates FLNa. (A) Cyclin B1/Cdk1 phosphorylate FLNa in vitro. (Upper panel) Puriﬁed recombinant cyclin B1/
Cdk1 (20 ng) phosphorylates human FLNa puriﬁed from HeLa cells (250 ng) in a time-dependent manner. BSA has no eﬀect on FLNa
phosphorylation. (Lower panel) Puriﬁed recombinant cyclin B1/Cdk1 phosphorylates human FLNa (250 ng) in a dose-dependent manner.
Incubation time was 60 min. Figures are the representative of three independent experiments. (B) Immunopuriﬁed cyclin B1/Cdk1 is able to
phosphorylate chicken gizzard FLN (top panel). As well, active recombinant cyclin B1/Cdk1 phosphorylates baculovirus puriﬁed human FLNa
(bottom panel). Phosphorylation in both cases is dose-dependent. Incubation time was 45 min. (C) FLNa in HeLa cells contains an mpm-2 epitope.
The upper panel shows a Western blot for FLNa from either a whole cell lysate (WCL) or mpm-2 immunoprecipitation and is blotted with FLNa.
The lower panel shows a Western blot for mpm-2 from HeLa cells that have been treated with 100 ng/ml nocodazole. There is increased abundance of
the FLNa mpm-2 epitope in the nocodazole treated lane.
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peats 12–15: serines 1436, 1533 and 1630. We next created
FLNa mutants where each of these serines is singly mutated
to non-phosphorylatable residues. We also generated a FLNa
variant where all three residues are mutated. As can be seen in
Fig. 7C, the mutation of 1436 dramatically reduces the ability
of the fragment to become phosphorylated. Mutants in 1533
and 1630 remain phosphorylated, but to a lesser extent that
in the wild type protein. We hypothesize that serines 1436,
1533 and 1630 are all phosphorylated by cyclin B1/Cdk1
in vitro, but phosphorylation of serine 1436 is somehow neces-
sary to direct the phosphorylation of serines 1533 and 1630.
Cyclin B1/Cdk1 was unable to phosphorylate the triple mu-
tant. These results suggest that serine 1436 is an in vitro cyclin
B1/Cdk1 phosphorylation site.4. Discussion
Here, we show that the cyclin B1/Cdk1 mitotic regulator
binds and phosphorylates FLNa and reduces its ability to gel-
ate actin in vitro. Using a yeast two-hybrid screen, we ﬁnd thatcyclin B1 binds to FLNa residues centred around FLNa repeat
9. The two proteins reciprocally co-immunoprecipitate in hu-
man cells and show speciﬁc co-localization in mitotic cells.
The minimal cyclin B1 residues that interact with FLNa are
amino acids 1–40.
Cyclin B1/Cdk1 can phosphorylate FLNa in vitro and this
phosphorylation reduces the ability of FLNa to gel actin.
Gelation by FLNa involves the solidiﬁcation of polymerized
actin into a cross-linked three-dimensional network, and is be-
lieved to reﬂect the ability of FLNa to create high-order actin
structures within cells [14]. Previously, chicken gizzard FLN
was identiﬁed as a substrate for calcium/calmodulin-dependent
protein kinase II (CaM kinase II) [35]. Using an in vitro gela-
tion assay, Ohta and Hartwig [35] demonstrated that the phos-
phorylation of FLN by CaM kinase II decreased its ability to
gel actin. This suggests that modulating FLNa’s ability to
cross-link actin in cells by phosphorylation is a mechanism
to regulate the mechanical properties of cytoplasmic actin net-
works. We found the incubation of FLNa with cyclin B1/
Cdk1, like CaMK II decreased its ability to gel actin. Since
we have observed that cyclin B1/Cdk1 can phosphorylate puri-
ﬁed FLNa concomitant with a reduction in gelation, we pre-
Fig. 6. Cyclin B1/Cdk1 are able to decrease FLNa gelation. (A) Cyclin B1/Cdk1 phosphorylation inhibits the ability of FLNa to gel actin. The left
panel shows that phosphorylation of FLNa by immunopuriﬁed cyclin B1/Cdk1 decreases its ability to gel actin. There is reduced actin content in lane
4 relative to lane 3. The histogram shows a densitinometric quanitation of gelled actin in three independent experiments. The amount of gelled actin is
normalized to the FLNa control. (B) Cdk1 kinase inhibitors rescue inhibition of FLNa gelation. Treatment of immunopuriﬁed cyclin B1/Cdk1 with
either roscovitine or olomoucine causes FLNa induced actin gelation to return to the same level as FLNa alone, indicating that the inhibition of
gelation caused by cyclin B1/Cdk1 is dependent on Cdk1 kinase activity. a-actinin acts as a positive control for actin gelation. The histogram shows a
densitinometric quanitation of gelled actin in three independent experiments. The amount of gelled actin is normalized to the FLNa control. (C) (Left
panel) Human FLNa (closed circles) increases the apparent viscosity of a solution of actin polymers (23 lM) in a dose-dependent fashion (left panel).
Open circles are FLNa without actin. (Right panel) Incubation of FLNa (200 nM) and actin with increasing concentrations of either active cyclin B1/
Cdk1 (closed circles) or BSA (open circles) are shown.. The treatment of FLNa with increasing concentrations of cyclin B1/Cdk1 reduces the ability
of FLNa to increase the apparent viscosity of a 23 lM actin solution (closed circles). Treatment of FLNa with BSA had no eﬀect on FLNa-
dependent viscosity changes (open circles). Figures are the representative of three independent experiments with triplicate viscosity measurements in
each.
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The mechanism by which phosphorylation of FLNa aﬀects its
ability to gel actin is, however, unknown; phosphorylation
may reduce FLNa’s ability to bind actin, to dimerize, or both.
While we observed the reduction of FLNa-dependent gela-
tion by cyclin B1/Cdk1, we do not know whether this has phys-
iological consequences in a living cell. We have transfectedactive cyclin B1 alleles into FLNa-deﬁcient M2 cells and their
FLNa containing A7 counterpart. M2 cells have defects in cell
locomotion and show high amounts of membrane blebbing
[14]. These defects have been rescued in the A7 cell line [38].
We reasoned that cyclin B1 should alter the actin cytoskeleton
in M2, but not A7. However, we were unable to conﬁdently
identify FLNa-dependent changes in actin structure upon
Fig. 7. Cyclin B1/Cdk1 phosphorylates FLNa at serine 1436. (A) Cyclin B1/Cdk1 preferentially phosphorylated a FLNa fragment containing repeats
11–16 (FLNa-3) (left panel). The positions of the FLNa fragments are seen in the Coomassie stained gel (right panel). All FLNa fragments were
produced as GST fusion proteins, which were treated with thrombin to release the protein fragment. (B) Generation of an in vitro mpm-2 site in
repeats 12–15. A recombinant GST protein containing repeats 12–15 was incubated with or without active cyclin B1/Cdk1 followed by Western
blotting for mpm2. (C) Mutation of serine 1436 greatly decreases the ability of cyclin B1/Cdk1 to phosphorylate FLNa repeats 12–15 (FLNA WT).
The triple mutation also shows greatly reduced phosphorylation (top panel). A schematic diagram for the partial FLNa constructs is shown (right
panel). The Coomassie stained gel appears in the bottom panel.
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FLNa-dependent pathway of actin remodelling is an idea that
requires further investigation. However, we have found that
FLNa contains an mpm-2 epitope in HeLa cells, consistent
with the idea that cyclin B1/Cdk1 could phosphorylate FLNa
in vivo and that FLNa might be a regulator of mitotic actin
remodelling.
We have identiﬁed serine 1436 as a major in vitro phospho-
acceptor site. Three FLNa serines (1436, 1533 and 1630) in re-
peats 12–15 match the Cdk1 consensus phosphorylation se-
quence (K/R) (S/T)P X(K/R) or (S/T)P X(K/R) [37].
Mutation of serine 1436 to non-phosphorylatable glycine dra-
matically reduced in vitro phosphorylation. However, muta-
tions of serines 1533 and 1630 also reduced phosphorylation.
We favour a model where serines 1436, 1533 and 1630 are
all phosphorylated by cyclin B1/Cdk1 in vitro, but phosphor-
ylation of serine 1436 is somehow necessary to direct the phos-phorylation of serines 1533 and 1630. Alternatively, 1436 may
be the only residue phosphorylated but the interaction between
cyclin B1/Cdk1 and serines 1533 and 1630 are necessary for
maximal 1436 phosphorylation. These three phospho-acceptor
sites are physically distinct from the cyclin B1 interaction site
on FLNa. Cyclin B1 binds to repeat 9 while serines 1436,
1533 and 1630 are in FLNa repeats 12, 13, and 14, respectively.
While we have identiﬁed 1436, 1533 and 1630 as in vitro cy-
clin B1 substrates, we have yet to identify a mechanism by
which these residues could aﬀect in vivo or in vitro gelation.
This issue is complicated because we have not yet been able
to conﬁdently establish an experimental system where the ecto-
pic expression of cyclin B1 modulates some facet of FLNa-
dependent actin remodelling in living cells (see above). In
addition, FLNa is a large 280 kDa protein and cyclin B1/cdk1
can phosphorylate FLNa fragments that do not contain
serines 1436, 1533 and 1630 (see Fig. 7A), suggesting that there
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do not yet know whether 1436, 1533, and 1630 are authentic
in vivo FLNa phosphorylation sites, and the mechanism by
which cyclin B1 alters in vitro FLNa/dependent gelation is cur-
rently unknown. As such, we have not yet determined whether
1436, 1533 and 1630 have an obligate role in mediating actin
gelation in vivo or in vitro. Other kinases known to phosphor-
ylate FLNa include p21-activated kinase 1 [31], protein kinase
Ca [32] and ribosomal S6 kinase [39] and these may co-operate
with Cdk1 to regulate FLNa activity. The comprehensive iden-
tiﬁcation of FLNa residues phosphorylated by cyclin B1/Cdk1
in vitro and in vivo is an important issue for continued study.
Cyclin B1 is one of the three proteins identiﬁed to date that
binds between the actin-binding domain and the ﬁrst hinge re-
gion of FLNa [14]. Protein kinase C a (PKCa), a member of a
family of phospholipid-dependent serine/threonine kinases was
found to bind FLNa between repeats 1–4 and repeats 22–24
[32]. The signiﬁcance of the binding however, between repeats
1–4 has not yet been fully determined. The other protein is fur-
in, a membrane associated endoprotease [40]. Interaction of
furin with FLNa results in its tethering to the cell surface,
allowing for the sorting of furin into its proper cellular com-
partments [40]. Other identiﬁed FLNa-interacting proteins
including TRAF2, SEK-1 and granzyme B, bind to repeats
in the carboxy-terminal portion between the hinges and the
dimerization domain [17,41,42]. While we ﬁnd that phosphor-
ylation by cyclin B1 reduces the ability of FLNa to gel actin, it
is also possible that FLNa phosphorylation could alter the
binding of other proteins to FLNa. However, this idea remains
to be explored.
To date, ﬁlamins have been found to interact with over 30
cellular proteins of great functional diversity [13]. Many ﬁl-
amin interacting proteins are involved in cell signalling and it
is believed that ﬁlamins physically connect several signalling
complexes to the actin cytoskeleton [13]. For example, FLNa
is known to act as a scaﬀold for b-arrestins (b-arr), multifunc-
tional adaptor proteins [43]. b-arr and FLNa act cooperatively
to activate the MAPK extracellular signal-regulated kinase
(ERK) because FLNa facilitates the formation of the b-arr–
ERK2 complex [43]. FLNa could act as a molecular scaﬀold
to recruit active cyclin B1/Cdk1 into a position where it can
phosphorylate other cytoskeletal regulatory proteins. The
knowledge that FLNa acts a scaﬀold for other proteins sug-
gests the possibility that it could recruit active cyclin B1/
Cdk1 and other proteins to the same position in a cell. For
example, the cyclin B1/Cdk1 complex has previously been re-
ported to phosphorylate actopaxin, caldesmon and paxillin,
focal adhesion proteins that associate with actin [28–30]. This
mitosis-dependent phosphorylation may play a role in co-ordi-
nating the disassembly of focal adhesions at the onset of mito-
sis. It is also observed that as cells progress out of mitosis,
actopaxin and paxillin become dephosphorylated, independent
of cell adhesion, suggesting that dephosphorylation of both
proteins precedes the establishment of post-mitotic cell-extra-
cellular matrix (ECM) adhesion [28]. It has been reported that
an early event in mitosis is the accumulation of active cyclin
B1/Cdk1 in the cytoplasm [44]. FLNa could potentially recruit
cyclin B1/Cdk1 to actopaxin, paxillin and caldesmon and other
cytoskeletal regulatory proteins [28–30]. However, the intracel-
lular localization of endogenous or transfected cyclin B1 was
largely similar between the M2 and A7 cell lines (not shown),
suggesting that FLNa does not have an obligate role in con-trolling cyclin B1 localization. It is probable that the large
number of actin cytoskeleton binding, cross-linking and regu-
lating proteins necessitates multiple pathways for actin rear-
rangement, some dependent on cyclin B1/Cdk1 and others not.
In summary, we ﬁnd that the cyclin B1/Cdk1 mitotic regula-
tor binds the actin cross-linking protein FLNa as well as
co-localizing with it. We also show that cyclin B1/Cdk1 phos-
phorylates FLNa and reduces its ability to gel actin. We have
identiﬁed serine 1436 as one site of cyclin B1/Cdk1 phosphor-
ylation in FLNa. Our observations are consistent with the idea
that cyclin B1/Cdk1’s phosphorylation of FLNa could play an
important role in regulating actin dynamics. This is interesting
considering the possibility that FLNa could be acting as a scaf-
fold allowing cyclin B1/Cdk1 to phosphorylate other actin
associated proteins such as caldesmon and paxillin at mitosis.
We believe that our observations provide evidence that cyclin
B1/Cdk1 are involved in the regulation of actin rearrangement
at the onset of mitosis and that the cyclin B1 binding and cy-
clin B1/Cdk1 phosphorylation of FLNa may represent only
one of many possible pathways leading to the control of actin
cross-linking at mitosis.
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